Renowned Global Biopharma Experts Join Apeiron Therapeutics' Advisory Committee to Advance Next-Gen CDK Inhibitor Pipeline

SHANGHAI, April 16, 2021 /PRNewswire/ -- Keith Lenden, Venture Partner at ARCH Ventures, and Dr. Honggang Bi, Senior Vice President at Covance Drug Development, a Labcorp company, have joined the Advisory Board of Apeiron Therapeutics (Apeiron).

The addition of Keith Lenden and Dr. Bi Honggang has enabled Apeiron Therapeutics to leverage its extensive expertise in drug innovation, translational medicine, and clinical development, while also expanding the company’s global perspective.

Keith Lenden is a seasoned entrepreneur and leader in the biotechnology and pharmaceutical industries, with an impressive track record in company formation, project leadership, corporate development, and product market strategy. Keith Lenden is a Venture Partner at ARCH Venture Partners and a co-founder of Autobahn Therapeutics, Boundless Bio, Receptos (acquired by Celgene), and Abide Therapeutics (acquired by H. Lundbeck A/S).

Dr. Honggang Bi currently serves as Global Senior Vice President of Covance, a Labcorp company, Head of Drug Development for the Asia-Pacific region, and General Manager for China. He is a global leader and expert in the fields of preclinical development, clinical trial testing, and clinical trial management. Prior to joining Covance, Dr. Bi held R&D leadership positions at companies including SmithKline Beecham, Parke-Davis, Pfizer, and Frontage, bringing over 28 years of industry experience.

The Apeiron Therapeutics Scientific Advisory Committee will help support the development of the company’s differentiated product portfolio, including a series of next-generation highly selective CDK inhibitors.